Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments Functional Independence Measure (total). Scale from: 0 to 126. Higher scores indicate less disability · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Partner abuse in the first 3 months postpartum (Current Abuse Score**) The Current abuse score consists of 2 scales: 1) Abuse Assessment Screen (AAS) and 2) Prenatal Psychosocial Profile (PPP). · pregnant women
1 finding from 1 review
Partner abuse: total episodes at final study assessment (pregnancy and up to 10 weeks postpartum) · pregnant women
Any intervention to prevent violence (all interventions) probably leads to lower partner abuse: total episodes at final study assessment (pregnancy… compared with standard care (moderate certainty).
1 finding from 1 review
Total clearance (at 4 weeks or less) Investigator's assessment · patients with seborrhoeic dermatitis
Calcineurin inhibitor showed no clear difference in total clearance (at 4 weeks or less) Investigator's assessment compared with steroid (low certainty).
1 finding from 1 review
Total clearance (at 4 weeks or less) Investigator's assessment · people with seborrhoeic dermatitis of the scalp or face
Steroid showed no clear difference in total clearance (at 4 weeks or less) Investigator's assessment compared with azole (moderate certainty).
1 finding from 1 review
Total clearance (at 4 weeks or less) Investigator's assessment · patients with seborrhoeic dermatitis
Strong steroid (class III or IV) showed no clear difference in total clearance (at 4 weeks or less) Investigator's assessment compared with mild steroid (class I or II) (moderate certainty).
1 finding from 1 review
Total clearance (more than 4 weeks) Investigator's assessment · patients with seborrhoeic dermatitis
Strong steroid (class III or IV) may leads to lower total clearance (more than 4 weeks) Investigator's assessment compared with mild steroid (class I or II) (low certainty).
1 finding from 1 review
Total clearance Investigator's assessment · patients with seborrhoeic dermatitis
Lithium may leads to higher total clearance Investigator's assessment compared with azole (low certainty).
1 finding from 1 review
Participant global assessment of success Not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Global assessment of treatment success · acute gout
Canakinumab probably leads to higher participant global assessment of response to treatment: good or… compared with triamcinolone acetonide (moderate certainty).
1 finding from 1 review
Functional assessment using a patient reported outcome measure: · adults with olecranon fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatigue · patients with paroxysmal nocturnal hemoglobinuria
1 finding from 1 review